Wegovy's maker is testing it for knee pain, sleep apnea
Novo Nordisk, the company behind Wegovy, is widening its focus—testing this popular weight-loss drug on conditions like knee osteoarthritis and sleep apnea, not just obesity or diabetes.
The goal? Address more of the 200+ health issues linked to obesity and help even more people.
What's in the pipeline?
Novo Nordisk isn't stopping at current drugs. Their next-gen therapy amycretin showed up to 24.3% weight loss in early trials—beating Wegovy—and bigger studies are planned for 2026.
Another treatment, CagriSema, helped nearly one in five patients lose over 30% of their body weight.
Meanwhile, they're also exploring if semaglutide, the active ingredient in Wegovy and Ozempic, could help with Alzheimer's disease.
Why this matters
If these expanded trials succeed, it could mean better options for treating a whole range of obesity-related problems—not just losing weight but improving quality of life for people with conditions like joint pain or sleep issues.
For anyone following health breakthroughs (or just curious about what's next), Novo Nordisk is definitely one to watch right now.